Biogen Inc. insider trading

Bought

$585.1

Sold

$239.7K

2 of 2 on a 10b5-1 plan

Net

−$239.2K

Insiders

2

• Minor Lloyd10b5-1

  Director

  −$119.2K

  Aug 04, 2026

  593 sh · $200.96

• Minor Lloyd10b5-1

  Director

  −$120.6K

  Aug 03, 2026

  593 sh · $203.34

• Murphy Nicole

  Head of Pharm Ops and Tech

  +$585.1

  Feb 12, 2026

  3 sh · $195.04

Largest purchase

+$151.6K of BIIB by Dorsa Caroline (Director) on May 02, 2025.

Largest sale

−$1.3M of BIIB by Sherwin Stephen A (Director) on Mar 07, 2025, under a 10b5-1 plan.

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

SEC industry classification

Biological Products, (No Diagnostic Substances)

Headquarters

Cambridge, MA

Incorporated in

DE

Listed on

Nasdaq

SEC Central Index Key

0000875045

Previously filed as

BIOGEN IDEC INC.

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

Open-market purchase (code P)

An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.

Grants and option exercises (codes A, M)

Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.

Cluster buy

Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Are BIIB insiders buying or selling?

Between Feb 12, 2026 and Aug 04, 2026, 2 Biogen Inc. insiders made 1 open-market purchase worth $585.1 and 2 sales worth $239.7K, a net sale of $239.2K. 2 of the sales were pre-scheduled under a Rule 10b5-1 plan.

How much BIIB stock have insiders bought and sold in the last two years?

Between Jul 01, 2024 and Jun 30, 2026, 5 Biogen Inc. insiders made 2 open-market purchases worth $152.1K and 8 sales worth $2.9M. Every one of the sales was pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 1 purchase ($585) and 4 sales ($1M). The largest purchase was Dorsa Caroline buying $151.6K on May 02, 2025. The largest sale was Sherwin Stephen A selling $1.3M on Mar 07, 2025.

What was the largest recent BIIB insider trade?

Minor Lloyd (Director) sold $120.6K of BIIB stock on Aug 03, 2026 at about $203.34 a share, under a pre-scheduled 10b5-1 plan.

When did an insider last buy BIIB shares?

The most recent open-market purchase on file is Murphy Nicole (Head of Pharm Ops and Tech) buying $585.1 on Feb 12, 2026.

Where does BIIB insider trading data come from?

From the Form 4 filings Biogen Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.